Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
NDA Filingmiv-celPositive
AI Analysis
Summary
Kyverna Therapeutics' miv-cel demonstrated improved mobility and favorable safety at one year in stiff person syndrome patients. The company plans to file for FDA priority review this year.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
one-year durability data showed improved mobility and favorable safety profile
Importance:8/10
Sentiment:
0.75
CAR-Tautoimmunestiff person syndromeFDA-firstpriority reviewdurability data
Related Companies
Read the original article
Published by BioSpace on September 24, 2026 1:27 PM